RNA-seq data are available for download from the National Center for Biotechnology Information Sequence Read Archive database (accession number: SRP102205).

Introduction {#sec001}
============

Mammalian STE20-like serine-threonine kinase MST1, encoded by the STK4 gene, is a multifunctional protein \[[@pone.0184590.ref001], [@pone.0184590.ref002]\]. MST1 and its closest paralogs MST2 (encoded by the STK3 gene), MST3, and MST4 are members of the Class II Germinal Center Family of Protein Kinases \[[@pone.0184590.ref003]\]. Here, we use STK4, an official gene name for MST1, to avoid confusion with the MST1 official gene name that encodes macrophage stimulating 1 or hepatocyte growth factor-like protein. STK3/4 and LATS1/2 (large tumor suppressor 1 and 2) are core kinase components of the Hippo tumor suppressor pathway in mammalians \[[@pone.0184590.ref004]\]. In the conventional Hippo pathway, the STK3/4 and LATS1/2 signaling cascade phosphorylates and inactivates the transcriptional coactivator YAP1 (yes associated protein 1) and its close paralog WWTR1 \[[@pone.0184590.ref005]\]. YAP1 and WWTR1 do not have DNA binding domains and they exert their biological outputs, such as cell proliferation and survival, by interacting with the TEAD1-4 transcription factors.

Lines of evidence have indicated that dysregulation or loss of STK4/Hippo signaling is linked to developmental disorders and carcinogenesis with poor prognosis \[[@pone.0184590.ref006]--[@pone.0184590.ref012]\]. For example, a genetic deletion of hippo (*hpo*) in *Drosophila* results in a tumor-like phenotype due to the loss of apoptosis \[[@pone.0184590.ref013]\]. Similarly, mice with the conditional STK3/4 gene knockouts show stem cell expansion, and tumorigenesis \[[@pone.0184590.ref011], [@pone.0184590.ref014], [@pone.0184590.ref015]\]. STK4 is a stress-induced kinase and it can be activated in response to cell-death inducers. Autophosphorylation of STK4 at Thr183 (Thr180 in STK3) in the activation loop is a key activation mechanism for STK4/3 because phosphorylation of Thr183/180 causes the cleavage of STK4 by caspases under apoptotic conditions \[[@pone.0184590.ref003], [@pone.0184590.ref016], [@pone.0184590.ref017]\]. The caspase-cleavage results in a more active STK4 protein (STK4-N, an amino-terminally truncated STK4), which localizes into the nucleus and induces apoptosis through histone modifications and chromatin condensations \[[@pone.0184590.ref018], [@pone.0184590.ref019]\].

Previously, we identified STK4 as a binding partner of AKT protein complexes that were isolated from lipid raft of the androgen-sensitive LNCaP prostate cancer (PC) cell line \[[@pone.0184590.ref007]\]. Lipid raft is the specialized cholesterol-rich membrane microdomain and plays a critical role in signal transductions and cell survival \[[@pone.0184590.ref020]--[@pone.0184590.ref023]\]. In that study, we demonstrated that levels of STK4 protein progressively declined during PC progression to the metastatic castration-resistant state, which coincided with the activation of AKT1 \[[@pone.0184590.ref007], [@pone.0184590.ref024]\]. In addition, we and others reported that DNA hypermethylation \[[@pone.0184590.ref017], [@pone.0184590.ref025]\] and post-translational modification \[[@pone.0184590.ref017], [@pone.0184590.ref025]\] meadiated the loss of STK4 activity. Interestingly, a recent study suggested that the dimerization of STK3 and STK4 that was mediated by H-ras signaling caused the loss of STK4 activity \[[@pone.0184590.ref026]\]. Moreover, we reported that the full-length STK4 (STK4-FL) enriched in cell nuclei, even in the presence of cell-death inducer, was devoid of Thr183 phosphorylation \[[@pone.0184590.ref025]\]. Nevertheless, how STK4 in a defined cell location regulates PC cell growth remains elusive.

In the present study, we developed and utilized the cytoplasm-, lipid raft- and nuclear-localized STK4 expressing PC cell models to gain more insights into the role of STK4 in aggressive PC. We found that STK4 enriched in the defined subcellular compartment differentially regulated cell growth *in vitro* and tumor growth *in vivo*. We identified several differentially expressed (DE) genes that responded to the enrichment of ectopic STK4 in all three cell compartments. Our functional annotation clustering showed that these DE genes were associated with a wide range of molecular pathways including tumor suppressor and oncogenesis as well as cellular metabolisms. Our findings suggest that STK4 signaling controls aggressive prostate tumor cell growth by modulating with multiple signaling mechanisms.

Materials and methods {#sec002}
=====================

Plasmids {#sec003}
--------

Construction of the tetracycline (Tet) or doxycycline (Dox)-inducible STK4 plasmid (pRX-HA-STK4) was described previously \[[@pone.0184590.ref027]\]. Dox is a tetracycline analog. To express Hemagglutinin (HA)-tagged STK4 protein in the lipid raft membrane domain, we constructed lipid raft (LR)-targeted pRX-LR-HA-STK4 mammalian expression vector. To generate pRX-LR-HA-STK4 vector, we took a series of approaches. First, we generated a pRX-LR-HA vector, for which double-stranded 5'-phosphorylated DNA consisting of palmitoylation and myristoylation (PM) signal from the Lck gene and the HA tag sequences were ligated into the BamH1 and NotI restriction enzyme (RE) sites in the pRetro-X-Pur (Pur: puromycin) retroviral vector (Clontech Laboratories, Inc.). The resulting vector was designated as pRX-PM-HA. Second, the PCR-amplified full-length STK4 cDNA was inserted into the NotI and MluI enzyme sites in the pRX-PM-HA vector. To express HA-tagged STK4 protein in the nucleus, we constructed nuclear (NL)-targeted pRX-NL-HA-STK4 mammalian expression vector. To construct pRX-NL-HA-STK4, first, we generated pRX-3NLS-HA vector, for which double-stranded 5'-phosphorylated DNA containing three consecutive copies of nuclear localization signal (3NLS) from SV40 large T-antigen separated with three base-pair spacers and HA-tag sequences were ligated into the BamH1 and NotI RE sites in the pRetro-X-Pur retroviral vector. The resulting vector was designated as pRX-NLS-HA. Second, the PCR-amplified full length STK4 cDNA was inserted into the NotI and MluI RE sites in the pRX-3NLS-HA vector. AccuPrime^™^ Pfx SuperMix (Invitrogen; Grand Island, NY) was used in PCR reactions. Standard molecular biology techniques in cloning and DH5-α competent cells in plasmid amplification were utilized \[[@pone.0184590.ref027]\]. In-frame and fidelity of all constructs were confirmed by DNA sequencing.

Cell models {#sec004}
-----------

Establishment of Tet or Dox-responsive C4-2/Vector and C4-2/HA-STK4 cell models was previously described \[[@pone.0184590.ref027]\]. Here, we renamed the C4-2/HA-STK4 cell as C4-2/CL-STK4 because we noted that ectopic expression of HA-STK4 was naturally accumulated in the cytoplasm (\[[@pone.0184590.ref027]\] and [Fig 1A and 1D](#pone.0184590.g001){ref-type="fig"}). To establish the C4-2/LR-STK4 cell model, first retrovirus carrying pRX-LR-HA-STK4 and pRX-NL-HA-STK4 vector were produced in HEK-293T cells as previously described \[[@pone.0184590.ref027]\]. Then, C4-2/TetON cells were infected with retrovirus encoding pRX-LR-HA-STK4 or pRX-NL-HA-STK4 vector, followed by Puromycin (Pur) selection (3 μg/mL) to generate Tet-inducible C4-2/LR-HA-STK4 or C4-2/NS-HA-STK4 expressing cells. We designated these cells as C4-2/LR-STK4 and C4-2/NL-STK4, respectively. All protocols and procedures were performed according to the manufacturer\'s instructions (Clontech Laboratories, Inc.). Growth conditions for C4-2 and HEK 292T cells were previously described \[[@pone.0184590.ref027]\].

![Expression of CL-STK4, LR-STK4, and NL-STK4 protein in Tet-inducible C4-2 prostate cancer cells.\
**(A)** Time-dependent expression of CL-STK4, LR-STK4, and NL-STK4 protein in the engineered cells that were exposed to doxycycline (Dox) for 24 and 48h. Levels of ectopic STK4 proteins were assessed by Western blotting (WB) using the HA-tagged antibody. (**B-D)** Analysis of CL-STK4, LR-STK4, and NL-STK4 protein in cytoplasmic, lipid raft, and nuclear fractions, respectively. Expression of HA-STK4 protein was evaluated by WB with the HA-tag antibody at 48h after treatment with and without doxycycline (Dox, 4 μg/ml). Lam (lamin) A/C was used as a nuclear marker. G~i~α2 was used as a lipid raft marker. **(E-G)** Immunofluorescence (IF) analysis of CL-STK4, LR-STK4, and NL-STK4 protein in the C4-2/CL-STK4, C4-2/LR-STK4, and C4-2/NL-STK4 cells, respectively. IF was performed at 24h post Dox (4 μg/ml) treatment. Micrographs are the representation of two independent experiments. CTxB-FITC labeled lipid raft in C4-2/LR-STK4 cells. For both experiments, cells were grown in Tet-approved serum conditions. CL: Cytoplasmic localization, LR: Lipid raft; NL: nuclear localization, HA: Hemagglutinin.](pone.0184590.g001){#pone.0184590.g001}

Protein analysis {#sec005}
----------------

Cytoplasmic and nuclear fractions were prepared using our established method \[[@pone.0184590.ref028]\]. TS (Triton-X-100-soluble) fraction and TI (Triton-X-100 insoluble, but *n*-octyl-β-D-glucoside soluble) fraction---TI fraction by definition, represents lipid raft---were isolated according to the established protocol \[[@pone.0184590.ref007], [@pone.0184590.ref029]\]. Presence of ectopic HA-tagged STK4 protein in cytoplasmic, lipid raft and nuclear fractions was determined by Western blotting using the HA antibody (Covance). Briefly, proteins were resolved by SDS-PAGE. PBST (0.1% Tween-20) containing 5% (w/v) skim milk powder or PBST containing 5% immunoglobulin G (IgG)-free bovine serum albumin (Sigma-Aldrich) was used in membrane blocking and antibody dilutions. Giα2 protein was included as a negative and positive control for TS and TI fractionations, respectively. Lamin A/C (Cell Signaling Technology) was used as a negative and positive control for cytoplasmic and nuclear fractionations, respectively \[[@pone.0184590.ref027]\]. Signals were visualized by chemiluminescence method (GE HealthCare).

Growth assays {#sec006}
-------------

C4-2/Vector, C4-2/CL-STK4, C4-2/LR-STK4 and C4-2/NL-STK4 cells were seeded in tissue culture medium supplemented with 10% Tet-approved serum in 96-well cell culture plate. Cells were then treated with Dox (3 μ/ml) for 72h to induce STK4 expression in the cell. Cell growth was assessed by imaging and MTS assay. For imaging, cells were washed with PBS and bright-field images were captured using microscopy (Nikon Eclipse *Ti* model; USA) at 20x magnification. CellTiter 96 AQueous system was used to assess cell growth according to manufacturer's protocol (Promega) and as described \[[@pone.0184590.ref027]\]. This system uses MTS and it has been widely used to evaluate cell growth in cultures \[[@pone.0184590.ref027]\].

Immunofluorescence {#sec007}
------------------

Immunofluorescence analysis of HA-STK4 protein in C4-2 cells was performed with modifications \[[@pone.0184590.ref027]\]. Briefly, cells were fixed with freshly prepared 4% PFA (paraformaldehyde that was prepared in PBS) for 30 min and permeabilized with 0.2% Triton-X-100 and incubated with anti-HA (Covance, 1:50) antibody overnight at 4°C. Cells were washed with PBS after each step. In addition, lipid rafts were labeled with CTxB-FITC conjugated (Sigma-Aldrich) as described \[[@pone.0184590.ref021]\]. Briefly, live cells were washed with cold PBS and incubated with CTxB-FITC (20 ng/ml, which was prepared in cold serum-free media) on ice for 30 min prior to fixation with 4% PFA. Alexa Fluor 532 conjugated anti-mouse (1:1000 dilution) was used to detect HA-STK4 signals in the cell. Slides were mounted with VectaShield containing DAPI (Vector Labs, H-1200). Immunofluorescence images were captured by microscopy (Zeiss 700) at 40x magnification with oil immersion.

Xenograft assays {#sec008}
----------------

C4-2/Vector, C4-2/LR-STK4, and C4-2/NL-STK4 cells mixed with Matrigel (1:1 ratio) were implanted subcutaneously at the right and left flanks of the nude and immunocompromised male mice (n = 10 per condition). 1×10^6^ cells/100 μL were used per injection per site under anesthesia by isoflurane. Starting 24h post cell inoculation, mice were treated with Dox (0.5 mg/mL) in drinking water for 6 weeks to induce STK4 expression. A weekly tumor size measurement was assessed by caliper manually \[[@pone.0184590.ref027], [@pone.0184590.ref029]\]. Upon completion of the experiment, mice were sacrificed by humane way (by CO~2~ inhalation, followed by cervical dislocation) and tumor tissues extracted from mice were fixed in 5% formaldehyde or "snap" frozen at −80°C for future analysis. Animal study was conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at Cedars-Sinai Medical Center. All experimental procedures in live animals were performed under isoflurane anesthesia and all efforts were made to minimize suffering. Mice were euthanized by CO~2~ inhalation, followed by cervical dislocation." Student\'s t-test (two-tailed) was used to determine the significance between the two groups. *P*-value ≤ 0.05 was considered significant.

RNA isolation and sequencing {#sec009}
----------------------------

Total RNA in biological replicates was isolated from C4-2/Vector, C4-2/CL-STK4, C4-2/LR-STK4, and C4-2/NL-STK4 cells using RNA isolation kit according to manufacturer's instruction (Life Technologies). Cells were grown in 10% Tet-approved serum-fed conditions at 80% confluence prior to RNA isolation. Quality of total RNA was assessed prior to library construction. RNA-sequencing (RNAseq) libraries were prepared using the standard protocol and sequenced by Illumina Genome Analyzer IIx in Genomic Core at Cedar-Sinai Medical Center.

RNAseq data analysis {#sec010}
--------------------

The quality of 72 base-pair reads was assessed with FastQC 0.10.1 software \[[@pone.0184590.ref030]\]. FastQC identifies lingering TruSeq adapter sequences present on reads. We used cutadapt tool to trim low quality base pairs and the TruSeq adapter sequences from the end of reads \[[@pone.0184590.ref031]\]. The reads were then aligned against the Illumina iGenomes Homo Sapiens NCBI build 37.2 reference sequence using Tophat 2.2.08b \[[@pone.0184590.ref032]\]. To compute DE genes, gene counts (i.e., number of sequence reads assigned to each gene) were calculated using htseq-count tool \[[@pone.0184590.ref033]\]. The gene count data were fed into DESeq2 Bioconductor package in R to identify DE genes using the false discovery rate (FDR) and fold change cutoffs \[[@pone.0184590.ref034]\]. To demonstrate the consistency of transcript abundance between replicates, scatterplot of the DESeq2 normalized gene counts were plotted in R.

Gene ontology and pathway enrichment analysis {#sec011}
---------------------------------------------

To compute the functional annotation of the DE genes, we performed gene ontology (GO) \[[@pone.0184590.ref035]\] and KEGG pathway \[[@pone.0184590.ref036]\] enrichment analysis using STRINGDb Bioconductor package (version 1.14.0) in R \[[@pone.0184590.ref037]\]. All transcripts in Homo Sapiens NCBI build 37.2 were used as background and Benjamini-Hochberg based FDR threshold of 0.05 was used to select significant GO biological process terms and KEGG pathways for each DE gene list \[[@pone.0184590.ref038]\]. We visualized the top 20 enriched KEGG pathways and GO terms in a bar chart using the lattice library (version 0.20--34) in R. We computed the union of top 20 enriched KEGG pathways/GO terms and displayed the significant FDR values (i.e., ≤ 0.05) of these pathways/terms in the three conditions.

Network enrichment analysis of DE genes {#sec012}
---------------------------------------

Reactome Functional Interaction (FI) plugin in Cytoscape was used to study the known functional interactions among the DE genes \[[@pone.0184590.ref039]\]. First, we imported the DE genes to build a network of known functional interactions among the DE genes using the most recent Reactome FI Network annotation (version 2015). In this network, each node is a DE gene and edges represent the known functional interactions. We filtered the network by removing computationally predicted interactions and genes with zero degree (i.e., did not have any functional interaction to any other gene in the network). We clustered nodes into modules using "Cluster FI Network" function in Reactome FI plugin. We performed GO biological process enrichment on modules of size ≥ 10 and determined a representative GO term for each module by examining the GO enrichment results manually. Finally, we edited the network by setting the layout to "grouping by module ID", labeling each module by its GO term, coloring nodes based on their upregulation/downregulation status, and adjusting the size of nodes and the font size of node labels proportional to their degree (i.e., number of interactions that they have).

Availability of RNAseq data {#sec013}
---------------------------

RNAseq data are available for download from the National Center for Biotechnology Information Sequence Read Archive database (Accession Number: SRP102205).

Results {#sec014}
=======

Establishment of lipid raft and nuclear localized STK4 prostate cancer cell models {#sec015}
----------------------------------------------------------------------------------

To better understand the effects of STK4 enriched in the cytoplasm, lipid raft and nucleus on cell growth and gene expression in PC, first we established the Tet-inducible lipid raft (LR)- and nuclear (NL)-localized STK4 expressing C4-2 cell models in addition to the cytoplasm (CL)-localized STK4 expressing C4-2 cell model. Previously, we described the establishment of CL-localized STK4 C4-2 cell, which was included as a control in this study \[[@pone.0184590.ref027]\]. The Tet-inducible system allowed us to control STK4 expression in the cell. We designated these cell models as C4-2/CL-STK4, C4-2/LR-STK4, and C4-2/NL-STK4 cells ([Fig 1A--1C](#pone.0184590.g001){ref-type="fig"}). In this study, we utilized the C4-2 cell line because it is the castration-resistant subline of LNCaP cells and expresses significantly lower levels of STK4 transcript and protein than parental LNCaP \[[@pone.0184590.ref024]\]. Ectopic expression of STK4 protein in the engineered C4-2 cells was analyzed by Western blotting ([Fig 1A--1D](#pone.0184590.g001){ref-type="fig"}). First, we showed that doxycycline (Dox, a tetracycline analog) exposure increased the expression of ectopic CL-STK4, LR-STK4, and NL-STK4 in a time-dependent manner relative to the no Dox treatment ([Fig 1A](#pone.0184590.g001){ref-type="fig"}). Second, we demonstrated that ectopic STK4 protein was primarily enriched in the intended subcellular locations: cytoplasm in C4-2/CL-STK4 cell ([Fig 1B](#pone.0184590.g001){ref-type="fig"}), lipid raft in C4-2/LR-STK4 ([Fig 1C](#pone.0184590.g001){ref-type="fig"}), and nucleus in C4-2/NL-STK4 ([Fig 1D](#pone.0184590.g001){ref-type="fig"}) cells. Here, it is worth mentioning that the cleavage of ectopic STK4 protein (i.e. STK4-N) due to the overexpression was not detectible by Western blotting under these experimental conditions (not shown). In addition, we performed immunofluorescence imaging to verify the subcellular localization of ectopic CL-STK4, LR-STK4, and NL-STK4 protein ([Fig 1E, 1F and 1G](#pone.0184590.g001){ref-type="fig"}, respectively).

STK4 enriched in cytoplasm, lipid raft, and nucleus differentially regulates cell growth {#sec016}
----------------------------------------------------------------------------------------

To determine whether cytoplasmic-, lipid raft-, and nuclear STK4 distinctly regulate cell growth *in vitro*, C4-2/CL-STK4, C4-2/LR-STK4, C4-2/NL-STK4 and C4-2/Vector (mock) cells were exposed to Dox to induce ectopic STK4 expression in the cell. C4-2/CL-STK4 and C4-2/Vector were included as a positive and negative control, respectively, to accurately evaluate the effects of LR-STK4 and NL-STK4 on C4-2 cell growth ([Fig 2A and 2B](#pone.0184590.g002){ref-type="fig"}). The results showed that the growth suppressive effects of LR-STK4 were significantly greater than NL-STK4 and CL-STK4 (*P \< 0*.*01*). CL-STK4 showed the least inhibitory effects on cell growth, which is consistent with our earlier observation \[[@pone.0184590.ref027]\]. Therefore, the degree of growth suppression by STK4 is LR-STK4 \> NL-STK4 \> CL-STK4.

![Regulation of C4-2 cell growth by STK4 signaling in all three subcellular locations.\
**(A)** Representative bright field images of C4-2/Vector, C4-2/CL-STK4, C4-2/LR-STK4, and C4-2/NL-STK4 cells. Cell images were captured at 72h post to Dox treatment (4 μg/ml). (**B)** Growth of C4-2/Vector, C4-2/CL-STK4, C4-2/LR-STK4, and C4-2/NL-STK4 cells *in vitro*. Cell growth was determined by MTS assay at 72h post Dox exposure. Data (±SD) are the representation of two independent experiments in triplicates, \*, \*\*, \*\*\**P \< 0.007*. (**C)** Prostate tumor xenografts in mice (n = 10 per conditions). C4-2/Vector, C4-2/LR-STK4, and C4-2/NL-STK4 cells were subcutaneously inoculated into the intact nude, immunocompromised male mice. Animals were treated with Dox (0.5 mg/ml) for 6 weeks in drinking water. Tumor sizes were measured weekly for 5 weeks. Tumor growth (volumes) was presented as a function of time, \*, \*\**P \< 0*.*01*. (**D)** Growth of C4-2/LR-STK4 cells treated with and without Dox and epidermal growth factor (EGF). Cell growth was determined by MTS assay at 72h post Dox and/or EGF treatment, \*, \*\**P \< 0*.*001*. Data (±SD) are the representation of two independent experiments in triplicates.](pone.0184590.g002){#pone.0184590.g002}

To determine the biological significance of the above findings, we conducted xenograft experiments in mice, according to a protocol approved by the IACUC. C4-2/LR-STK4, C4-2/NL-STK4, and C4-2/Vector cells were implanted under the skin of the hormonally intact and immunocompromised male mice (n = 10 per condition). Mice were fed with Dox in drinking water to induce STK4 expression in tumor cells. The results demonstrated that C4-2/LR-STK4 and C4-2/NL-STK4 cells formed much smaller tumors in number and size than C4-2/Vector ([Fig 2C](#pone.0184590.g002){ref-type="fig"}).

We noted that *in vitro* and *in vivo* growth suppression caused by the induction of LR-STK4 did not correlate. One possible explanation for it was that the growth suppressive effects of LR-STK4 might be attenuated. Evidence suggested that growth factors or cytokines could negatively regulate STK4 signaling \[[@pone.0184590.ref017], [@pone.0184590.ref040]--[@pone.0184590.ref042]\]. Indeed, treatment of LR-STK4 cells with epidermal growth factor (EGF) significantly reversed the growth inhibitory effects of LR-STK4 relative to the mock control ([Fig 2D](#pone.0184590.g002){ref-type="fig"}), indicating that our observations were internally consistent.

STK4 enriched in cytoplasm, lipid raft, and nucleus differentially regulates gene expression {#sec017}
--------------------------------------------------------------------------------------------

To determine whether the enrichment of STK4 signaling in the cytoplasm, lipid raft, and nucleus changes the gene expression patterns of C4-2 cells, we performed mRNA expression profiling of mock, CL-STK4, LR-STK4, and NL-STK4 cell using RNAseq (see [Materials & methods](#sec002){ref-type="sec"}). First, our statistical and bioinformatics analysis of the RNAseq data showed that the normalized gene counts between replicates were highly correlated ([S1 Fig](#pone.0184590.s001){ref-type="supplementary-material"}), indicating that technical variability of the sequencing between replicates were minimal. Second, we identified a list of DE genes with respect to the vector control using DESeq2. The FDR and fold change values computed by DESeq2 for all genes in all three STK4 conditions are shown in the [S1 Table](#pone.0184590.s003){ref-type="supplementary-material"}. To determine DE genes, we used absolute log2 fold change values ≥ 2, False Discovery Rate (FDR) ≤ 0.01 cutoffs for LR-STK4, and NL-STK4 cells. To increase the number of DE genes for CL-STK4 cells, however, we used a slightly less stringent fold change cutoff (absolute log2 fold change ≥ 1.5; FDR ≤ 0.01). The results, as illustrated in volcano plots ([Fig 3A](#pone.0184590.g003){ref-type="fig"}), heatmap ([Fig 3B](#pone.0184590.g003){ref-type="fig"}) and Venn diagram ([Fig 3C](#pone.0184590.g003){ref-type="fig"}) demonstrated that the number of DE genes in NL-STK4 and LR-STK4 cells were much greater than CL-STK4, and about 90% DE genes in NL-STK4 and LR-STK4 cells overlap. As detailed in the Venn diagram ([Fig 3C](#pone.0184590.g003){ref-type="fig"}), CL-STK4 cells resulted in 332 DE genes (226 upregulated and 106 downregulated), LR-STK4 cells resulted in 3032 DE genes (1780 upregulated and 1252 downregulated), and NL-STK4 cells resulted in 3265 DE genes (1938 upregulated and 1327 downregulated). The complete list of DE genes identified from CL-STK4, LR-STK4, and NL-STK4 cells are shown in [S2](#pone.0184590.s004){ref-type="supplementary-material"}--[S4](#pone.0184590.s006){ref-type="supplementary-material"} Tables, respectively. The top 100 DE genes in each condition are shown in [Table 1](#pone.0184590.t001){ref-type="table"}. There were 192 DE genes intersected with STK4 expression in all three subcellular compartments ([Table 2](#pone.0184590.t002){ref-type="table"}). Among the intersected DE genes, seven of them were downregulated in CL-STK4, but upregulated in NL-STK4 and LR-STK4 cells, and 28 of them were upregulated in CL-STK4, but downregulated in NL-STK4 and LR-STK4 cells ([Table 2](#pone.0184590.t002){ref-type="table"}). There were 2830 DE genes intersected in NL-STK4 and LR-STK4 cells ([Fig 3C](#pone.0184590.g003){ref-type="fig"}).

![Overview of the RNAseq data and the validation.\
**(A)** Volcano plots of DE genes from the DESeq2 analysis. **(B)** Heatmap of DE genes using fold-change values in all three STK4 conditions (**C)** Venn diagram of DE genes in C4-2/CL-STK4, C4-2/LR-STK4, and C4-2/NL-STK4 cells. **(D)** Quantitative RT-PCR analysis of select DE genes, \**P \< 0*.*01*. Data are representation of the two independent experiments in duplicates.](pone.0184590.g003){#pone.0184590.g003}

10.1371/journal.pone.0184590.t001

###### Top 100 DE genes regulated by the enrichment of STK4 in three subcellular locations (*FDR ≤ 0*.*01*).

Numbers are in log2 fold change. Minus signs indicate downregulation with respect to the vector control.

![](pone.0184590.t001){#pone.0184590.t001g}

  Entrez ID   Gene Symbol   CL-STK4   Entrez ID   Gene Symbol   LR-STK4   Entrez ID   Gene Symbol   NL-STK4
  ----------- ------------- --------- ----------- ------------- --------- ----------- ------------- ---------
  2042        EPHA3         -4.00     10417       SPON2         -8.14     158471      PRUNE2        -8.36
  54898       ELOVL2        -3.41     3817        KLK2          -7.88     4311        MME           -7.19
  6860        SYT4          -2.92     354         KLK3          -7.28     367         AR            -7.05
  1644        DDC           2.84      26298       EHF           -6.42     8611        PPAP2A        -6.78
  1836        SLC26A2       -2.78     7345        UCHL1         6.41      7345        UCHL1         6.74
  55504       TNFRSF19      -2.70     158471      PRUNE2        -6.22     4128        MAOA          -6.71
  7982        ST7           2.66      85414       SLC45A3       -6.16     4824        NKX3-1        -6.52
  2181        ACSL3         -2.39     9415        FADS2         -5.83     999         CDH1          -6.39
  2887        GRB10         2.39      2042        EPHA3         -5.75     85414       SLC45A3       -6.00
  2289        FKBP5         -2.12     4824        NKX3-1        -5.72     2042        EPHA3         -5.94
  64853       AIDA          1.99      999         CDH1          -5.37     9415        FADS2         -5.91
  444         ASPH          1.65      8611        PPAP2A        -5.29     56937       PMEPA1        -5.57
  8287        USP9Y         3.16      2346        FOLH1         -5.27     200916      RPL22L1       -5.47
  58480       RHOU          -2.10     4128        MAOA          -5.17     6720        SREBF1        -5.41
  79884       MAP9          -2.36     4311        MME           -5.14     2182        ACSL4         5.41
  23671       TMEFF2        -4.99     154796      AMOT          4.97      261729      STEAP2        -5.31
  1846        DUSP4         -2.64     2182        ACSL4         4.95      4784        NFIX          -5.14
  60481       ELOVL5        -1.64     1021        CDK6          4.76      3169        FOXA1         -5.13
  2982        GUCY1A3       -1.75     3169        FOXA1         -4.71     4685        NCAM2         -5.09
  79993       ELOVL7        -1.58     367         AR            -4.67     154796      AMOT          5.06
  22936       ELL2          -1.84     200916      RPL22L1       -4.66     6482        ST3GAL1       -4.97
  1948        EFNB2         -2.07     1803        DPP4          -4.66     5567        PRKACB        -4.96
  54491       FAM105A       -2.15     55504       TNFRSF19      -4.63     1803        DPP4          -4.95
  563         AZGP1         -1.83     283349      RASSF3        -4.60     1021        CDK6          4.92
  3158        HMGCS2        2.49      5567        PRKACB        -4.56     283349      RASSF3        -4.74
  3479        IGF1          -3.24     9590        AKAP12        4.55      94241       TP53INP1      -4.74
  57007       ACKR3         2.87      23052       ENDOD1        -4.38     10982       MAPRE2        4.71
  4430        MYO1B         -1.96     6652        SORD          -4.37     26872       STEAP1        -4.65
  6192        RPS4Y1        2.20      3315        HSPB1         -4.34     9590        AKAP12        4.62
  4094        MAF           -4.42     94241       TP53INP1      -4.27     55504       TNFRSF19      -4.61
  9518        GDF15         2.03      4784        NFIX          -4.27     4324        MMP15         -4.61
  1026        CDKN1A        1.70      80031       SEMA6D        4.25      26084       ARHGEF26      -4.55
  79822       ARHGAP28      -1.51     7782        SLC30A4       -4.23     7782        SLC30A4       -4.49
  2550        GABBR1        2.15      261729      STEAP2        -4.20     3315        HSPB1         -4.48
  10602       CDC42EP3      -2.44     79993       ELOVL7        -4.17     7431        VIM           4.43
  4285        MIPEP         -1.52     4685        NCAM2         -4.15     439921      MXRA7         4.39
  85414       SLC45A3       -1.65     26084       ARHGEF26      -4.15     6652        SORD          -4.37
  56937       PMEPA1        -1.60     114569      MAL2          -4.08     10129       FRY           -4.35
  9687        GREB1         -1.86     6482        ST3GAL1       -4.03     79993       ELOVL7        -4.35
  120         ADD3          1.71      4436        MSH2          3.87      80031       SEMA6D        4.29
  4316        MMP7          5.48      3909        LAMA3         -3.82     23052       ENDOD1        -4.29
  8756        ADAM7         -4.84     5358        PLS3          3.82      3909        LAMA3         -4.27
  445         ASS1          1.58      27347       STK39         -3.76     6678        SPARC         4.26
  4100        MAGEA1        1.84      23705       CADM1         3.65      286077      FAM83H        -4.22
  84898       PLXDC2        3.94      1534        CYB561        -3.65     9515        STXBP5L       -4.18
  147381      CBLN2         5.02      25874       MPC2          -3.63     114569      MAL2          -4.11
  8653        DDX3Y         2.06      10481       HOXB13        -3.62     3716        JAK1          4.06
  3899        AFF3          -1.56     22998       LIMCH1        -3.59     4436        MSH2          4.00
  23266       LPHN2         -2.08     11057       ABHD2         -3.58     22998       LIMCH1        -3.95
  1292        COL6A2        1.53      667         DST           3.56      25874       MPC2          -3.91
  1001        CDH3          2.92      22894       DIS3          3.53      11057       ABHD2         -3.82
  4109        MAGEA10       4.63      2982        GUCY1A3       -3.47     22894       DIS3          3.79
  4857        NOVA1         2.36      5580        PRKCD         -3.41     27347       STK39         -3.75
  1135        CHRNA2        -2.40     55748       CNDP2         -3.37     25923       ATL3          -3.74
  57633       LRRN1         1.73      25923       ATL3          -3.37     5358        PLS3          3.72
  3397        ID1           -1.86     10257       ABCC4         -3.32     10481       HOXB13        -3.67
  10551       AGR2          -3.40     57221       KIAA1244      -3.25     57683       ZDBF2         3.65
  8612        PPAP2C        1.89      60481       ELOVL5        -3.23     1534        CYB561        -3.56
  4233        MET           3.42      2181        ACSL3         -3.23     23705       CADM1         3.55
  138046      RALYL         -2.96     2335        FN1           -3.05     667         DST           3.54
  162394      SLFN5         1.58      23195       MDN1          3.02      2335        FN1           -3.44
  285025      CCDC141       -2.76     11167       FSTL1         2.99      57221       KIAA1244      -3.41
  54842       MFSD6         1.86      23327       NEDD4L        -2.93     55748       CNDP2         -3.39
  116443      GRIN3A        1.87      6675        UAP1          -2.89     22873       DZIP1         3.35
  1740        DLG2          -2.69     5836        PYGL          2.86      64780       MICAL1        -3.31
  80150       ASRGL1        -1.83     55884       WSB2          -2.84     2982        GUCY1A3       -3.28
  3934        LCN2          2.35      3417        IDH1          -2.81     5580        PRKCD         -3.28
  4137        MAPT          1.72      288         ANK3          -2.75     7105        TSPAN6        3.25
  23467       NPTXR         1.79      56994       CHPT1         -2.74     9882        TBC1D4        3.22
  6091        ROBO1         -1.63     7764        ZNF217        -2.71     56204       FAM214A       -3.17
  90362       FAM110B       -1.55     5530        PPP3CA        -2.70     64839       FBXL17        -3.14
  4664        NAB1          2.07      55704       CCDC88A       2.69      60481       ELOVL5        -3.13
  9783        RIMS3         2.37      2289        FKBP5         -2.50     5836        PYGL          3.11
  389206      BEND4         -1.71     3992        FADS1         -2.43     2181        ACSL3         -3.11
  6286        S100P         -2.03     79718       TBL1XR1       -2.42     5530        PPP3CA        -3.04
  330         BIRC3         1.91      57222       ERGIC1        -2.39     1528        CYB5A         -3.02
  5796        PTPRK         1.97      55827       DCAF6         -2.38     11167       FSTL1         3.01
  5801        PTPRR         3.23      2195        FAT1          2.30      57211       GPR126        -2.96
  57628       DPP10         3.56      7163        TPD52         -2.28     51347       TAOK3         -2.95
  51351       ZNF117        2.05      8826        IQGAP1        2.25      928         CD9           -2.88
  79674       VEPH1         -2.65     64062       RBM26         2.24      288         ANK3          -2.85
  64881       PCDH20        2.63      2194        FASN          -2.22     22936       ELL2          -2.85
  2026        ENO2          1.95      23013       SPEN          2.19      6091        ROBO1         2.84
  10133       OPTN          2.20      29968       PSAT1         -2.10     23327       NEDD4L        -2.83
  5066        PAM           1.87      6747        SSR3          -2.03     4942        OAT           2.82
  7102        TSPAN7        4.40      6678        SPARC         4.19      7764        ZNF217        -2.81
  80031       SEMA6D        -4.13     51347       TAOK3         -3.23     56994       CHPT1         -2.80
  26053       AUTS2         1.78      9882        TBC1D4        3.10      55884       WSB2          -2.79
  284119      PTRF          2.13      56937       PMEPA1        -5.13     57619       SHROOM3       -2.74
  162514      TRPV3         -2.41     6091        ROBO1         2.79      6675        UAP1          -2.70
  5268        SERPINB5      1.65      159195      USP54         -2.51     55704       CCDC88A       2.70
  9644        SH3PXD2A      1.59      2235        FECH          -2.55     3417        IDH1          -2.69
  55243       KIRREL        3.62      57211       GPR126        -2.86     1174        AP1S1         -2.69
  4117        MAK           -1.67     57683       ZDBF2         3.45      79718       TBL1XR1       -2.63
  3371        TNC           1.71      2131        EXT1          3.50      1946        EFNA5         -2.63
  57562       KIAA1377      2.32      7431        VIM           4.54      5768        QSOX1         -2.62
  10158       PDZK1IP1      1.51      440         ASNS          -2.34     159195      USP54         -2.61
  9086        EIF1AY        1.85      23657       SLC7A11       -3.54     51166       AADAT         -2.60
  8284        KDM5D         1.64      51635       DHRS7         -2.74     57222       ERGIC1        -2.54
  5352        PLOD2         1.57      595         CCND1         -2.25     3304        HSPA1B        2.52
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###### Common DE genes regulated by the enrichment of STK4 in three subcellular locations *(FDR ≤ 0*.*01)*.

Numbers are in log2 fold change. Minus signs indicate downregulation with respect to the vector control.
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  Entrez ID   Gene Symbol   CL-STK4   LR-STK4   NL-STK4   Entrez ID   Gene Symbol   CL-STK4   LR-STK4   NL-STK4
  ----------- ------------- --------- --------- --------- ----------- ------------- --------- --------- ---------
  23316       CUX2          -1.61     2.64      2.8       3113        HLA-DPA1      2.03      4.98      4.8
  3087        HHEX          -2.09     2.33      2.4       3239        HOXD13        1.70      7.53      7.6
  3400        ID4           -2.00     3.57      3.5       11255       HRH3          -1.53     -3.61     -3.8
  5064        PALM          -2.19     2.76      2.8       9951        HS3ST4        -3.12     -4.71     -5.3
  6091        ROBO1         -1.63     2.79      2.8       3434        IFIT1         1.86      2.86      2.7
  80031       SEMA6D        -4.13     4.25      4.3       3479        IGF1          -3.24     -6.94     -8.7
  57713       SFMBT2        -1.60     4.41      4.4       3751        KCND2         -1.58     -3.06     -3.7
  57007       ACKR3         2.87      -2.45     -5.7      57562       KIAA1377      2.32      3.17      2.9
  6364        CCL20         1.74      -3.12     -4.5      3798        KIF5A         2.68      6.71      6.6
  51816       CECR1         2.08      -2.60     -2.6      55243       KIRREL        3.62      6.78      6.8
  170712      COX7B2        2.12      -2.71     -3.9      84894       LINGO1        1.84      3.70      3.9
  1644        DDC           2.84      -3.41     -7.1      54947       LPCAT2        1.92      4.68      5.0
  8653        DDX3Y         2.06      -4.39     -7.1      84230       LRRC8C        1.99      5.70      5.6
  9086        EIF1AY        1.85      -3.23     -5.2      130576      LYPD6B        2.36      2.40      3.1
  9518        GDF15         2.03      -6.69     -7.5      4117        MAK           -1.67     -2.40     -2.3
  219970      GLYATL2       1.55      -3.86     -6.0      22983       MAST1         1.50      2.29      2.3
  3158        HMGCS2        2.49      -3.53     -7.1      154141      MBOAT1        1.71      4.01      4.1
  153572      IRX2          1.76      -3.08     -3.6      2122        MECOM         2.76      5.13      5.0
  8284        KDM5D         1.64      -3.18     -5.7      4233        MET           3.42      6.10      6.2
  3934        LCN2          2.35      -3.90     -4.9      11320       MGAT4A        2.14      3.91      3.9
  57633       LRRN1         1.73      -4.01     -6.5      4281        MID1          2.09      7.94      7.8
  4100        MAGEA1        1.84      -3.60     -7.4      4285        MIPEP         -1.52     -2.76     -2.4
  4316        MMP7          5.48      -3.03     -3.6      26002       MOXD1         2.85      7.08      7.6
  22829       NLGN4Y        1.53      -3.68     -4.3      4664        NAB1          2.07      3.12      3.3
  10158       PDZK1IP1      1.51      -4.07     -6.6      57701       NCKAP5L       1.62      2.41      2.6
  5284        PIGR          1.82      -2.72     -2.8      23114       NFASC         1.57      2.58      2.3
  8612        PPAP2C        1.89      -3.94     -5.9      7025        NR2F1         1.61      3.62      3.3
  64063       PRSS22        1.73      -3.55     -4.1      2908        NR3C1         2.58      8.50      8.3
  5696        PSMB8         2.53      -2.10     -2.6      4922        NTS           2.08      4.71      4.7
  6192        RPS4Y1        2.20      -3.63     -7.8      93145       OLFM2         2.42      2.62      2.5
  5268        SERPINB5      1.65      -4.31     -5.5      10133       OPTN          2.20      2.02      2.1
  8764        TNFRSF14      1.62      -3.95     -4.2      390190      OR5B2         -2.17     -3.93     -4.5
  7367        UGT2B17       1.63      -2.16     -4.7      5066        PAM           1.87      3.88      4.0
  8287        USP9Y         3.16      -2.47     -6.6      64881       PCDH20        2.63      2.51      2.9
  7404        UTY           2.08      -2.79     -4.9      56034       PDGFC         2.02      6.40      6.4
  728763      AC104809.3    -1.89     -4.27     -4.9      114770      PGLYRP2       -2.23     -5.75     -6.8
  2181        ACSL3         -2.39     -3.23     -3.1      5241        PGR           2.90      6.04      6.1
  23305       ACSL6         1.75      3.86      3.6       5569        PKIA          2.53      5.84      5.9
  10863       ADAM28        -2.48     -4.17     -3.6      51365       PLA1A         -2.18     -5.94     -6.6
  8756        ADAM7         -4.84     -7.51     -8.2      440107      PLEKHG7       -1.51     -3.55     -4.1
  150         ADRA2A        -1.72     -4.08     -5.9      5352        PLOD2         1.57      3.94      4.3
  100130776   AGAP2-AS1     1.58      3.05      3.4       84898       PLXDC2        3.94      3.66      3.4
  10551       AGR2          -3.40     -7.05     -7.1      56937       PMEPA1        -1.60     -5.13     -5.6
  183         AGT           -1.96     -4.95     -5.1      57718       PPP4R4        1.93      2.56      2.8
  57491       AHRR          1.52      5.95      6.2       5743        PTGS2         1.53      2.96      3.8
  115701      ALPK2         -2.23     -3.52     -3.7      5796        PTPRK         1.97      3.36      3.3
  347902      AMIGO2        1.83      3.16      3.3       284119      PTRF          2.13      2.65      2.9
  319         APOF          -1.82     -4.53     -4.7      138046      RALYL         -2.96     -6.93     -7.6
  79822       ARHGAP28      -1.51     -2.60     -2.6      11069       RAPGEF4       1.51      4.05      4.2
  115557      ARHGEF25      1.81      2.30      2.4       85004       RERG          2.02      3.99      4.3
  26053       AUTS2         1.78      3.23      3.1       10287       RGS19         1.70      3.28      3.3
  563         AZGP1         -1.83     -7.37     -10.2     58480       RHOU          -2.10     -2.27     -2.4
  25825       BACE2         1.98      3.56      3.5       9783        RIMS3         2.37      2.45      2.4
  54796       BNC2          2.07      4.92      4.9       140730      RIMS4         1.51      6.12      6.2
  89927       C16orf45      1.92      2.32      2.2       57484       RNF150        1.54      4.52      4.6
  767         CA8           3.00      6.92      7.3       221687      RNF182        2.10      3.82      3.8
  57118       CAMK1D        1.91      3.68      3.9       6286        S100P         -2.03     -6.00     -5.5
  858         CAV2          3.15      6.26      6.5       55511       SAGE1         -2.23     -4.94     -5.6
  285025      CCDC141       -2.76     -4.30     -4.8      389432      SAMD5         2.55      3.04      3.0
  159989      CCDC67        -2.41     -4.89     -5.5      54809       SAMD9         2.68      3.25      3.8
  151887      CCDC80        2.66      5.68      5.3       6326        SCN2A         2.46      4.71      4.6
  9308        CD83          1.68      2.84      2.7       56256       SERTAD4       2.46      6.28      6.1
  64781       CERK          2.54      5.64      5.7       9644        SH3PXD2A      1.59      3.65      3.8
  1135        CHRNA2        -2.40     -7.59     -8.3      6565        SLC15A2       -1.65     -2.46     -2.1
  9435        CHST2         2.14      4.65      4.9       7781        SLC30A3       2.20      5.05      5.0
  7123        CLEC3B        -1.51     -3.95     -4.1      55089       SLC38A4       -3.73     -2.73     -2.1
  80034       CSRNP3        2.12      3.16      3.2       85414       SLC45A3       -1.65     -6.16     -6.0
  1519        CTSO          -1.57     -2.58     -2.2      146857      SLFN13        2.50      3.17      3.0
  10563       CXCL13        -2.96     -4.32     -4.4      84189       SLITRK6       -1.68     -3.89     -3.5
  80319       CXXC4         2.35      5.90      5.8       8406        SRPX          2.25      2.73      2.8
  260293      CYP4X1        2.04      2.66      3.1       7903        ST8SIA4       2.61      2.73      3.4
  1740        DLG2          -2.69     -3.44     -3.8      6769        STAC          2.32      4.58      4.6
  93099       DMKN          1.60      5.54      5.8       112755      STX1B         1.83      4.45      4.9
  10655       DMRT2         -1.69     -3.91     -4.0      55061       SUSD4         1.54      2.47      3.0
  1846        DUSP4         -2.64     -3.71     -3.5      221711      SYCP2L        1.75      4.82      4.8
  80303       EFHD1         1.50      4.55      4.8       23345       SYNE1         1.90      4.46      4.4
  22936       ELL2          -1.84     -3.10     -2.8      11346       SYNPO         1.52      2.86      2.7
  54898       ELOVL2        -3.41     -2.33     -2.1      6857        SYT1          1.72      4.63      5.0
  60481       ELOVL5        -1.64     -3.23     -3.1      6860        SYT4          -2.92     -6.38     -8.5
  79993       ELOVL7        -1.58     -4.17     -4.3      80731       THSD7B        -1.91     -3.73     -4.0
  2026        ENO2          1.95      3.18      3.4       23671       TMEFF2        -4.99     -6.34     -6.3
  2042        EPHA3         -4.00     -5.75     -5.9      55321       TMEM74B       2.55      3.90      3.7
  2119        ETV5          1.88      3.40      4.3       3371        TNC           1.71      4.63      3.9
  90362       FAM110B       -1.55     -2.47     -2.4      55504       TNFRSF19      -2.70     -4.63     -4.6
  9715        FAM131B       1.85      3.45      4.1       23043       TNIK          1.64      3.97      3.8
  23359       FAM189A1      2.02      2.02      2.0       84951       TNS4          -1.94     -5.00     -5.3
  2217        FCGRT         2.29      4.06      4.2       10345       TRDN          -1.76     -5.87     -6.3
  9638        FEZ1          1.90      2.14      2.8       117854      TRIM6         1.74      4.92      5.0
  2289        FKBP5         -2.12     -2.50     -2.3      7220        TRPC1         1.89      6.36      6.6
  121643      FOXN4         2.14      2.19      2.2       162514      TRPV3         -2.41     -3.49     -3.7
  53827       FXYD5         2.27      6.68      7.0       10100       TSPAN2        1.78      5.64      6.1
  2550        GABBR1        2.15      2.39      2.2       7102        TSPAN7        4.40      5.84      5.8
  2706        GJB2          1.72      2.16      3.1       23508       TTC9          1.55      2.72      2.7
  647309      GMNC          -1.95     -3.46     -5.3      10382       TUBB4A        1.52      2.80      2.8
  387509      GPR153        1.50      3.25      3.1       54490       UGT2B28       -2.08     -4.54     -5.2
  2982        GUCY1A3       -1.75     -3.47     -3.3      79674       VEPH1         -2.65     -5.42     -6.2

To validate our RNAseq data, we analyzed the levels of KLK3, FKBP5, and MYC mRNA expression in the engineered C4-2 cells. We selected these genes because (i) their expressions were differentially regulated by STK4 in all three conditions ([S1 Table](#pone.0184590.s003){ref-type="supplementary-material"}), (ii) KLK3 and FKBP5 are well-known targets of AR that is also negatively regulated by STK4 \[[@pone.0184590.ref043]\] and (iii) MYC is a YAP/TEAD target and it intersected with STK4 signaling in PC cells \[[@pone.0184590.ref024]\]. Our RNAseq data revealed that expression of KLK3 was inhibited 7-fold in LR-STK4 and 13-fold in NL-STK4 cells. Similarly, expression of FKBP5 was inhibited 2-fold in CL-STK4, 2.5-fold in LR-STK4, and 2.3-fold in NL-STK4 cells. In addition, expression of MYC was inhibited 1.6-fold in LR-STK4 and NL-STK4 cells. These fold change values are in log2. Induction of CL-STK4 inhibited the expression of KLK3 and MYC less than half fold. Our quantitative PCR analysis verified the RNAseq data that, indeed, STK4 expression in all three cell compartments differentially regulates the expression of KLK3, FKBP5, and MYC ([Fig 3D](#pone.0184590.g003){ref-type="fig"}). We also examined the impact of STK4 on the AR pathway genes ([Table 3](#pone.0184590.t003){ref-type="table"}) obtained from Wikipathways \[[@pone.0184590.ref044]\]. The results showed that several AR targets were upregulated or downregulated by STK4 expression in these subcellular compartments, further validating our RNAseq data.
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###### Fold change values of AR targets in response to STK4 enrichment in all three subcellular compartments *(FDR ≤ 0*.*01)*.

Fold change values are in log2. Minus signs indicate downregulation with respect to the vector control.
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  Entrez ID   Gene Symbol   CL-STK4   LR-STK4   NL-STK4   Entrez ID   Gene Symbol   CL-STK4   LR-STK4   NL-STK4
  ----------- ------------- --------- --------- --------- ----------- ------------- --------- --------- ---------
  367         AR            0.28      -4.67     -7.05     9612        NCOR2         0.09      -0.97     -0.99
  595         CCND1         -0.05     -2.25     -2.04     1499        CTNNB1        0.15      0.41      0.43
  8611        PPAP2A        -0.18     -5.29     -6.78     860         RUNX2         -0.71     -1.48     -1.74
  57178       ZMIZ1         0.24      -1.71     -1.81     5925        RB1           0.44      0.61      0.75
  23028       KDM1A         -0.34     1.06      1.28      8648        NCOA1         -0.02     -0.55     -0.63
  3725        JUN           0.25      2.52      2.54      10401       PIAS3         0.43      -0.72     -0.74
  1956        EGFR          0.77      -2.41     -2.36     1387        CREBBP        -0.29     0.53      0.53
  4088        SMAD3         0.93      2.94      2.95      2119        ETV5          1.88      3.40      4.32
  998         CDC42         -0.14     1.64      1.75      898         CCNE1         -0.14     0.47      0.80
  354         KLK3          -0.71     -7.28     -13.71    2033        EP300         -0.12     0.35      0.35
  24149       ZNF318        0.34      1.44      1.48      29893       PSMC3IP       -0.31     0.61      0.85
  811         CALR          -0.06     -1.49     -1.11     10499       NCOA2         0.13      -0.46     -0.47
  1026        CDKN1A        1.70      -2.11     -1.95     6714        SRC           0.05      -0.66     -0.61
  573         BAG1          0.22      -2.03     -1.78     5728        PTEN          0.20      0.54      0.44
  6093        ROCK1         -0.01     0.98      1.12      11034       DSTN          -0.10     0.61      0.54
  5901        RAN           -0.39     0.64      0.72      90427       BMF           -0.35     -0.54     -0.90
  11143       KAT7          0.05      0.91      1.21      2288        FKBP4         -0.10     -0.31     -0.23
  9475        ROCK2         0.20      0.91      1.05      23598       PATZ1         -0.03     0.45      0.53
  207         AKT1          0.16      -1.03     -1.11     64800       EFCAB6        0.27      2.63      2.62
  9611        NCOR1         0.33      0.69      0.86      7041        TGFB1I1       0.40      1.79      3.00
  2308        FOXO1         -0.26     1.58      1.85      11315       PARK7         -0.22     -0.21     -0.21
  2932        GSK3B         0.03      -0.79     -0.92     1385        CREB1         -0.10     -0.37     -0.43
  6774        STAT3         0.24      -1.06     -0.90     25942       SIN3A         0.19      0.08      0.19
  2274        FHL2          -0.34     3.70      3.66      8554        PIAS1         -0.53     -0.38     -0.26
  672         BRCA1         -0.26     0.83      0.97      3065        HDAC1         -0.11     0.05      0.15
  387         RHOA          0.06      0.54      0.57      7329        UBE2I         -0.04     -0.19     -0.19
  7341        SUMO1         -0.13     0.80      0.87      6667        SP1           0.17      0.33      0.17
  8850        KAT2B         0.21      1.20      1.28      6013        RLN1          0.36      -2.68     -2.21
  10273       STUB1         0.11      -1.77     -1.77     4193        MDM2          0.42      -0.10     -0.16
  5052        PRDX1         0.31      0.56      0.65      5970        RELA          0.26      0.01      0.16
  5295        PIK3R1        0.12      -1.06     -1.39     5879        RAC1          -0.10     0.03      0.10
  6049        RNF6          -0.15     -1.17     -0.86     388         RHOB          0.42      0.22      0.17
  7337        UBE3A         -0.13     -0.82     -0.68     5296        PIK3R2        -0.22     -0.78     -1.21
  5747        PTK2          -0.10     0.66      0.61      9604        RNF14         -0.17     0.00      -0.07
  166         AES           0.24      -0.84     -0.77     8202        NCOA3         0.30      -0.08     0.06
  23411       SIRT1         -0.33     0.97      1.00      5883        RAD9A         0.24      0.12      -0.10
  10399       GNB2L1        0.17      0.37      0.36      56924       PAK6          0.36      -1.07     0.55
  857         CAV1          1.09      6.33      6.42      8431        NR0B2         0.14      0.84      0.69
  3985        LIMK2         -0.39     -0.73     -0.85     10524       KAT5          0.11      -0.24     -0.09
  6605        SMARCE1       -0.05     0.71      0.93      6047        RNF4          -0.05     -0.19     -0.04
  1616        DAXX          0.12      0.67      0.66      4089        SMAD4         0.06      0.04      -0.03
  7050        TGIF1         0.24      -1.23     -1.24     7182        NR2C2         0.15      -0.01     -0.03
  9063        PIAS2         0.24      -0.98     -0.84     51588       PIAS4         0.01      0.29      -0.03
  10498       CARM1         0.09      0.93      0.83      2316        FLNA          -0.19     -0.03     0.01

In addition, we compared our DE genes to the known putative oncogenes and tumor suppressors \[[@pone.0184590.ref045], [@pone.0184590.ref046]\]. [Fig 4](#pone.0184590.g004){ref-type="fig"} shows that enrichment of STK4 in all three subcellular compartments selectively regulated the expression of putative oncogenes and tumor suppressors. Many of these genes are directly linked to the AR pathway (e.g. FOXA1, SPOP, NCOR1/2, and ZBTB16), the DNA repair mechanism (e.g. MLH1 and MSH2), a member of the EST factors (e.g. ERG, ETV1/4/5, and FLH1), and cycle regulators (e.g. CDKN1A and CDKN2B). These genes and pathways are suggested to play a critical role in PC biology including metastatic CRPC \[[@pone.0184590.ref045], [@pone.0184590.ref046]\].

![STK4 selectively regulates the expression of putative oncogenes and tumor suppressors.\
Log2 fold change values for a list of putative oncogenes (black) and tumor suppressors (orange) in CL-STK4, LR-STK4, and NL-STK4 cells.](pone.0184590.g004){#pone.0184590.g004}

DE genes regulated by STK4 signaling are associated with multiple biological pathways {#sec018}
-------------------------------------------------------------------------------------

To gain insights into the biological processes and pathways associated with DE genes, we performed KEGG pathway and Gene Ontology (GO) biological processes enrichment analysis using STRINGdb package in R \[[@pone.0184590.ref037]\]. We found 45, 214, and 216 KEGG pathways enriched by DE genes in CL-STK4, LR-STK4, and NL-STK4 cells, respectively ([S5](#pone.0184590.s007){ref-type="supplementary-material"}--[S7](#pone.0184590.s009){ref-type="supplementary-material"} Tables). There were eight and five KEGG pathways uniquely enriched in LR-STK4 and NL-STK4 cells, respectively. On the other hand, there were no KEGG pathways uniquely enriched in CL-STK4 cells. Top 20 enriched KEGG pathways are shown in [Fig 5A](#pone.0184590.g005){ref-type="fig"} and the complete results are shown in [S5](#pone.0184590.s007){ref-type="supplementary-material"}--[S7](#pone.0184590.s009){ref-type="supplementary-material"} Tables. The KEGG pathway enrichment results show that majority of the top enriched pathways (e.g., Metabolic pathways, PI3K-AKT signaling, Pathways in cancer, Focal adhesion, Axon guidance, MAPK signaling, and Fatty acid metabolism) are common in all three conditions. Due to the large number of DE genes in NL-STK4 and LR-STK4 conditions, GO enrichment analysis returned over 2,000 terms. Top 20 enriched GO biological process terms are shown in [Fig 5B](#pone.0184590.g005){ref-type="fig"} and complete results are shown in [S8](#pone.0184590.s010){ref-type="supplementary-material"}--[S10](#pone.0184590.s012){ref-type="supplementary-material"} Tables. Top GO terms included terms such as development, proliferation, differentiation, axonogenesis, metabolic process, and cell adhesion.

![Top 20 KEGG pathways and GO biological process terms enriched by DE genes in all three STK4 cells.\
Each term in the bar chart appears in the top 20 **(A)** KEGG pathways **(B)** GO biological process terms enriched by DE genes in at least one condition. Red, blue, and green bars refer to the log2 enrichment FDR values in CL-STK4, LR-STK4, and NL-STK4, respectively. The terms with missing FDR values for CL-STK4 indicate that the DE genes in CL-STK4 were not significantly enriched for those terms.](pone.0184590.g005){#pone.0184590.g005}

In addition, because STK4 is a potent inhibitor of the YAP1/WWTR1-dependent transcriptions, we evaluated the status of YAP1/WWTR1 targets with respect to the subcellular localization of STK4 ([S11 Table](#pone.0184590.s013){ref-type="supplementary-material"}). We obtained 48 YAP1/WWTR1 targets from published studies \[[@pone.0184590.ref047]--[@pone.0184590.ref050]\]. We also illustrated the expression status of the Hippo pathway components in CL-STK4 ([Fig 6A](#pone.0184590.g006){ref-type="fig"}), NL-STK4 ([Fig 6B](#pone.0184590.g006){ref-type="fig"}), and LR-STK4 ([S2 Fig](#pone.0184590.s002){ref-type="supplementary-material"}) cells. The results of these investigations demonstrated that CL-STK4 modestly and distinctly altered the expression of YAP1/WWTR1 targets and the Hippo pathway members compared with LR-STK4 and NL-STK4. For example, CL-STK4 slightly increased STK3 and LLGL2 transcripts while LR-STK4 and NL-STK4 downregulated LLGL2 without affecting STK3 transcripts. In addition, LR-STK4 and NL-STK4 differentially regulated YAP1/WWTR1 targets ([Fig 6B](#pone.0184590.g006){ref-type="fig"}). For instance, LR-STK4 downregulated YAP1 target ITGB2, whereas NL-STK4 had no effect. Likewise, CL-STK4 and LR-STK4 slightly increased YAP1 expression, but NL-STK4 did not.

![KEGG Hippo signaling pathway.\
Each gene is colored by gene expression fold change in (A) CL-STK4 (B) NL-STK4 conditions using Cytoscape. Red: Upregulated, green: downregulated, white: not differentially expressed. Edge labels "e": expression interaction, "+p": phosphorylation, "-p": dephosphorylation.](pone.0184590.g006){#pone.0184590.g006}

DE genes in NL-STK4 and LR-STK4 cells associate with overlapping and unique modules {#sec019}
-----------------------------------------------------------------------------------

We investigated known functional interactions between DE genes in each condition using Reactome FI plugin in Cytoscape \[[@pone.0184590.ref051]\]. We built an interaction network of DE genes based on known functional interactions and clustered the network into modules. We annotated each module with a significantly enriched GO term (see [Materials & methods](#sec002){ref-type="sec"}). The annotated networks of DE genes for LR-STK4 and NL-STK4 cells were shown in Figs [7](#pone.0184590.g007){ref-type="fig"} and [8](#pone.0184590.g008){ref-type="fig"}, respectively. Because a few number of DE genes existed in CL-STK4 cells, the network annotation for those DE genes were not performed. The interaction network of NL-STK4 had 1086 genes grouped into 18 modules of size ≥ 10 genes. The interaction network of LR-STK4 had 974 genes grouped into 17 modules of size ≥ 10 genes. Both networks had eight common module annotations such as gene transcription, cell adhesion, and axon guidance, which also appeared in the KEGG pathway enrichment results. The NL-STK4 network had unique GO terms such as WNT signaling, RAS signaling, JAK/STAT signaling, and metabolic processes whereas the LR-STK4 network had unique GO terms such as cell migration, lipid metabolism, and ECM organization. Since clustering of the nodes were not based on GO annotation of genes, but solely based on the known functional interactions between the genes, some modules were enriched in the same GO term, namely gene transcription, cell adhesion, and axon guidance. These findings indicate that STK4/Hippo signaling initiating from or transiting through lipid raft or cell nuclei not only has overlapping functions but it also confers unique functions in regulating cell growth.

![Network enrichment annotation of DE genes in NL-STK4 cells.\
DE genes in NL-STK4 cells that have known functional interactions were clustered based on their connectivity in the network using Reactome FI plugin in Cytoscape. Each clustered module was annotated to a representative significantly-enriched GO term. Each edge represents a known interaction between two genes (i.e., nodes) in the network.](pone.0184590.g007){#pone.0184590.g007}

![Network enrichment annotation of DE genes in LR-STK4 cells.\
DE genes in LR-STK4 cells that have known functional interactions were clustered based on their connectivity in the network using Reactome FI plugin in Cytoscape. Each clustered module was annotated to a representative significantly-enriched GO term. Each edge represents a known interaction between two genes (i.e., nodes) in the network.](pone.0184590.g008){#pone.0184590.g008}

Discussion {#sec020}
==========

In this study, we have demonstrated that controlled expression of STK4, primarily enriched in the cytoplasm, lipid raft, and nucleus, differentially regulates PC cell growth and gene expression. We have identified several DE genes whose expression is downregulated or upregulated by CL-STK4, LR-STK4, and NL-STK4 signaling in all three subcellular locations. Surprisingly, about 90% of DE genes that were regulated by LR-STK4 and NL-STK4 overlapped and the number of DE genes identified from LR-STK4 and NL-STK4 cells were much greater than CL-STK4 cells. Our functional annotation clustering showed that these DE genes were associated with a broad cellular biology including cell proliferation, differentiation, motility, adhesion, survival, apoptosis, axon guidance, and metabolisms. Overall, our data suggest that STK4 signaling transiting through or initiating from a different subcellular compartment may result in distinct gene expression patterns and cellular biology.

PC is the most commonly diagnosed malignancy and the second leading cause of cancer death among men in the US \[[@pone.0184590.ref052]\]. Because androgen hormone signaling plays a critical role in PC development, progression, and metastasis, androgen deprivation is the first line of therapy for patients with locally advanced disease \[[@pone.0184590.ref045], [@pone.0184590.ref046]\]. However, almost all patients who receive primary androgen deprivation therapy (ADT) develop metastatic CRPC \[[@pone.0184590.ref045], [@pone.0184590.ref046]\]. Evidence indicates that AR is still a key driver of metastatic CRPC cell growth and survival, even in the absence of sub-physiological levels of androgens and in the presence of the second generation of ADT such as abiraterone acetate (ABI), a direct inhibitor of CYP17A that is a key enzyme in the androgen biosynthesis pathway \[[@pone.0184590.ref053], [@pone.0184590.ref054]\] and enzalutamide (ENZ), a direct AR inhibitor \[[@pone.0184590.ref055]--[@pone.0184590.ref057]\]. However, nearly all men with metastatic CRPC who are treated with ABI and ENZ also develop resistance to these agents, albeit with unknown mechanisms.

Here, we showed that enrichment of STK4 in the cytoplasm, lipid raft, and nucleus selectively regulates AR transcript. We also showed that STK4 signaling depending on its subcellular locations suppressed AR transcript with varying degrees. We noted that although CL-STK4 slightly increased AR transcript, LR-STK4 and NL-STK4 reduced it 4.6- and 7-fold, respectively, which correlated with the inhibition of AR target genes such as FKBP5, KLK3, and TMPRSS2 \[[@pone.0184590.ref043], [@pone.0184590.ref058]\]. However, many AR targets were minimally affected or unaltered by the targeted STK4 signaling ([Table 3](#pone.0184590.t003){ref-type="table"}), suggesting that the regulation of AR targets by STK4 is selective or context-dependent. Previously, we reported that crosstalk between YAP1 and AR signaling could contribute to CRPC \[[@pone.0184590.ref029]\]. In that study, we showed that STK4 depletion increased YAP1/AR interaction, which coincided with CRPC cell growth. Therefore, it is possible that YAP1 may function as a key intermediate for the selective regulation of AR targets by STK4, but this warrants further investigation, which is not the subject of the current study.

Alterations of the DNA methylation, DNA repair, PI3K/AKT, RAS/RAF, WNT, and cell-cycle pathways are commonly observed both in primary prostate tumors \[[@pone.0184590.ref045]\] and metastatic CRPC \[[@pone.0184590.ref046]\]. Aberrant expression of the DNA repair genes such as MLH1 and MSH2 is implicated in advanced PC \[[@pone.0184590.ref059]\]. Here, we showed that LR-STK4 and NL-STK4, but not CL-STK4, reduced the expression of MLH1 about 5-fold while increasing MSH2 expression about 4-fold under the same growth conditions. Similarly, altered ZBTB16 (also known as PLZF1) signaling is also implicated in metastatic CRPC \[[@pone.0184590.ref046]\]. Induction of LR-STK4 and NL-STK4, but not of CL-STK4, downregulated the expression of ZBTB16 3.2-fold. ZBTB16 is an AR target gene \[[@pone.0184590.ref046]\]. Furthermore, CDKN2A and CDKN2B are potent suppressors of cell-cycle progression \[[@pone.0184590.ref046], [@pone.0184590.ref060]\]. LR-STK4 and NL-STK4 increased the expression of CDKN2B 3.4-fold. These findings suggest that STK4 restricts aggressive cancer cell growth by modulating key oncogenic pathways including DNA repair and cell cycle regulators.

STK4 is a key negative regulator of YAP1/WWTR1-mediated gene transcription and oncogenesis. Herein, our data demonstrated that ectopic STK4 protein enriched in the cytoplasm, lipid raft, and nucleus had differential effects on YAP1/WWTR1 and YAP1/WWTR1-dependent gene expression. We noted that unlike NL-STK4, CL-STK4 and LR-STK4 showed similar trends in regulating YAP1 expression, although about 90% of genes regulated by LR-STK4 and NL-STK4 overlapped. These observations suggest the possibility that (a) CL-STK4 regulates gene expression by signaling through YAP1/WWTR1, (b) LR-STK4 regulates gene expression by YAP1/WWTR1-dependent and YAP1/WWTR1-independent mechanisms, and (c) NL-STK4 most likely regulates gene expression independently of YAP1/WWTR1. Nevertheless, future studies are necessary to test these hypotheses. In summary, we identified several DE genes and molecular pathways that are responded to the targeted STK4 expression and these pathways are known to be biologically and clinically relevant to human cancer including PC. The model in [Fig 9](#pone.0184590.g009){ref-type="fig"} summarizes our main findings.

![Schematic representation of the current study.\
TFs: Transcription factors. DE: Differentially expressed.](pone.0184590.g009){#pone.0184590.g009}
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###### Correlations of gene counts between technical replicates.

Scatterplot of gene counts from the technical replicates show a high degree of correlation in all three conditions.

(TIF)
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Click here for additional data file.

###### KEGG Hippo signaling pathway.

Each gene is colored by gene expression fold change in LR-STK4 condition. Red: Upregulated, green: downregulated, white: not differentially expressed. Edge labels "e": expression interaction, "+p": phosphorylation, "-p": dephosphorylation.

(TIF)
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